Large-scale genomics studies of metastatic castration-resistant PCa (mCRPC) have revealed the enrichment for TP53 and AR alterations in PCa metastases compared to primary disease4 and the association between RB1 mutations and mCRPC outcome5,6. This evidence concerns the gene TP53 and posterior cortical atrophy.